Our newsletters are published five or six times a year, and are a great way to stay in touch with DMTC’s news and achievements. To receive our newsletter by email, you can sign up here.
If you’ve missed an article or the chance to read a recent newsletter, you can read recent editions here:
DMTC is proud to announce the release of its latest Annual Report, which is available online and is currently being distributed to key stakeholders.
The report summarises the activities and achievements of the DMTC community for the July 2016 – June 2017 period and highlights continuing efforts to deliver enhanced Defence capabilities while also investing in Australian industrial capacity and in the research leaders of the future.
Our report also looks forward to opportunities and strategic developments for DMTC and its industry and research partners in 2018 and beyond.
DMTC’s Medical Countermeasures Program is growing with Round 2 projects announced by the Minister for Defence Industry, the Hon Christopher Pyne MP.
Medical countermeasures (MCMs) are vaccines, therapeutics and/or diagnostics against chemical, biological and radiological threat, emerging infectious disease and pandemics.
The new projects follow on from the first round of DMTC’s MCM Program that has been underway for around 15 months.
With its priorities set by Defence, seed funding for the DMTC MCM program has been provided by CSIRO and the Defence Science & Technology Group through its Next Generation Technologies Fund (NGTF). The aim of the MCM program is to accelerate the advanced development and deployment of countermeasures, with technical expertise from industry and research partners.
Under DMTC’s proven co-investment model, funding provided by Government customer agencies is leveraged by contributions of cash and resources from industry and research partners.
The Minister’s press release is available here and more details will be available on our website as soon as contract negotiations and project agreements are complete.